Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics (Nasdaq: PSTV) announced the U.S. FDA granted Orphan Drug Designation to REYOBIQ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas, with the designation scope broadened to include progressive pediatric ependymoma. The company also noted FDA IND clearance for pediatric high-grade glioma and ependymoma and ongoing Phase 1/2 studies.
The designation offers potential benefits including seven years of market exclusivity, tax credits, and regulatory fee exemptions.
Plus Therapeutics (Nasdaq: PSTV) received an AMA PLA CPT code (0640U) for its CNSide® CSF Tumor Cell Enumeration (TCE) test, effective July 1, 2026.
This dedicated billing code establishes a unique reimbursement identifier to support payer claims processing, clinician adoption, national utilization tracking, and the Company’s ongoing U.S. commercial launch of CNSide diagnostics.
Plus Therapeutics (Nasdaq: PSTV) announced Highmark coverage for its CNSide® CSF Tumor Cell Enumeration (TCE) assay, effective April 1, 2026, expanding total covered lives from ~67 million to ~75 million.
The agreement supports patient access, may accelerate clinical adoption, and advances the company toward its 2026 objective of 150 million covered lives.
Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards on March 26, 2026 to two new employees under its 2015 New Employee Incentive Plan.
The awards total 300,000 stock options (10-year term, $0.243 exercise price) and 300,000 RSUs. Options vest over four years; RSUs vest over three years.
Plus Therapeutics (NASDAQ: PSTV) announced a 1-for-25 reverse stock split effective 12:01 a.m. ET on April 2, 2026, to increase its per-share trading price and comply with Nasdaq's $1.00 minimum bid requirement.
Outstanding shares will be reduced from ~171,550,698 to ~6,862,027, a new CUSIP 72941H806 will be assigned, fractional shares will be paid in cash, and equity awards and warrants will be adjusted.
Plus Therapeutics (Nasdaq: PSTV) appointed diagnostics veteran Ron Andrews to its Board of Directors on March 26, 2026. Andrews brings over 35 years in diagnostics, experience leading Abbott, Roche, Thermo Fisher units and public startups, and has been involved in >$600M capitalization and ~$15B in exits.
He will support scaling CNSide, a cerebrospinal-fluid diagnostic for leptomeningeal metastases, and advise strategy, fundraising and commercialization efforts for the company’s diagnostics business.
Plus Therapeutics (Nasdaq: PSTV) will present a health economics analysis at ISPOR 2026 showing the CNSide CSF assay could cut leptomeningeal metastases (LM) healthcare costs by ~40% (range 33%–47%).
Key figures: median inpatient admissions ~$20,000 (IQR $10,000–$30,000) and LM costs may exceed $100,000 per month; findings support U.S. commercialization efforts.
Plus Therapeutics (Nasdaq: PSTV) reported full-year 2025 results and provided 2026 milestones for REYOBIQ clinical programs and CNSide commercial rollout. Key highlights include a $15 million upsized public offering, $13.1 million cash and investments at year-end, CPT Category III reimbursement for convection-enhanced delivery, and expanded CNSide lab licensing to 49 states.
The company expects REYOBIQ ReSPECT-LM data in Q3 2026, ReSPECT-GBM data in Q4 2026, increased 2026 R&D and G&A spend, and targets >150 million payer coverage and Medicare pathway for CNSide.
Plus Therapeutics (NASDAQ: PSTV) announced the AMA CPT Editorial Panel approved a new Category III CPT code X566T to track convection-enhanced delivery (CED) used with REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The code will be published July 1, 2026 and effective for reporting January 1, 2027.
The company said the code enables standardized utilization tracking, may inform future coverage and reimbursement, and supports REYOBIQ commercialization while Plus advances clinical enrollment milestones in 2026.
Plus Therapeutics (NASDAQ: PSTV) provided a business update on REYOBIQ clinical progress and U.S. commercialization of CNSide, announcing an upsized $15 million offering to fund 2026 priorities and extend cash runway through 2027. Key 2026 milestones include REYOBIQ dose optimization and data in Q3 2026, ReSPECT-GBM data and FDA end-of-phase alignment in Q4 2026, commercial manufacturing scale-up, and ReSPECT-PBC Phase 1 enrollment. CNSide targets include coverage for 150 million US lives, Medicare/Medicaid coverage, >1,250 tests/year, and launch of additional CSF tumor characterization tests. A conference call and webcast are scheduled for January 22, 2026 at 9:00 a.m. ET.